Who Covid Vaccine Agreement

Andrea Taylor, who led Duke`s analysis, said the combination of pre-emption agreements and limits on the number of doses that can be produced over the next few years means „we are going into a scenario where rich countries will have vaccines and the poorest countries probably will not have access.“ COVAX, the vaccine pillar in the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovation (CEPI), Gavi, the Vaccine Alliance and the World Health Organization (WHO) in collaboration with vaccine manufacturers in developed and developing countries. It is the only global initiative that cooperates with governments and manufacturers to ensure that COVID 19 vaccines are available worldwide, both in higher- and low-income countries. To date, governments, vaccine manufacturers, organizations and individuals have allocated $1.4 billion ($1.1 billion) for vaccine research and development. „All vaccine manufacturers and pharmaceutical companies should pool their science and data and commit to transferring their technology so that we can start production. No one has committed. Recognizing that the first useful vaccines may be rare, licensed vaccines are first made available to a strictly targeted proportion of 3% of the population of participating countries, with up to 20% of the most vulnerable populations in each country over time. Until now, these issues have been on the sidelines of the vaccine discussion, particularly in the United States. Prior to the emergence of COVID-19, CEPI`s priority diseases were Ebola, Lassa virus, medium respiratory coronavirus, nipah virus, Rift Valley Fever and chikungunya virus. CEPI has also invested in platform technologies that can be used for rapid vaccines and immunoprophylactic development against unknown pathogens (Disease X). „Such unity in the context of the COVID 19 crisis gives us confidence that together we can ensure the equitable delivery of COVID vaccines worldwide,“ said Henrietta Fore, Executive Director of UNICEF. „With our global supply chain and presence on the ground in 190 countries, UNICEF is proud to support this historic effort.“ Covid-19: How a „hot vaccine“ could help India fight coronavirus, while vaccine distribution decisions initially provided under the program remain at the discretion of each country, it says it „encourages countries to review these recommendations and be transparent about their decision-making processes and the final use of the vaccine.“ 172 economies are currently in talks on the possibility of participating in COVAX, a global initiative to cooperate with vaccine manufacturers to enable countries around the world to have access to safe and effective vaccines on an equal footing once they have been approved and licensed.

COVAX currently has the world`s largest and most diversified COVID 19 vaccine portfolio, including nine vaccine candidates, nine more are being evaluated and discussions are underway with other mayor builders.